BNP Paribas Exane downgraded Hologic (HOLX) to Neutral from Outperform with a $79 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic’s Financial Health at Risk: Navigating Reimbursement and Guideline Challenges
- Hologic price target raised to $76 from $69 at Morgan Stanley
- Hologic Updates Restricted Stock Unit Award Agreement
- Cautious Hold Rating for Hologic Amid Strong Q4 Results and Future Uncertainties
- Hologic’s Mixed Performance and Acquisition Uncertainty Lead to Hold Rating